Public Act 102-0413 Public Act 0413 102ND GENERAL ASSEMBLY |
Public Act 102-0413 | HB0102 Enrolled | LRB102 04076 CPF 14092 b |
|
| AN ACT concerning health.
| Be it enacted by the People of the State of Illinois,
| represented in the General Assembly:
| Section 5. The School Code is amended by adding Section | 2-3.182 and by changing Section 22-30 as follows: | (105 ILCS 5/2-3.182 new) | Sec. 2-3.182. Anaphylactic policy for school districts. | (a) The State Board of Education, in consultation with the | Department of Public Health, shall establish an anaphylactic | policy for school districts setting forth guidelines and | procedures to be followed both for the prevention of | anaphylaxis and during a medical emergency resulting from | anaphylaxis. The policy shall be developed after consultation | with the advisory committee established pursuant to Section 5 | of the Critical Health Problems and Comprehensive Health | Education Act. In establishing the policy required under this | Section, the State Board shall consider existing requirements | and current and best practices for schools regarding allergies | and anaphylaxis. The State Board must also consider the | voluntary guidelines for managing food allergies in schools | issued by the United States Department of Health and Human | Services. | (b) The anaphylactic policy established under subsection |
| (a) shall include the following: | (1) A procedure and treatment plan, including | emergency protocols and responsibilities for school nurses | and other appropriate school personnel, for responding to | anaphylaxis. | (2) Requirements for a training course for appropriate | school personnel on preventing and responding to | anaphylaxis. | (3) A procedure and appropriate guidelines for the | development of an individualized emergency health care | plan for children with a food or other allergy that could | result in anaphylaxis. | (4) A communication plan for intake and dissemination | of information provided by this State regarding children | with a food or other allergy that could result in | anaphylaxis, including a discussion of methods, | treatments, and therapies to reduce the risk of allergic | reactions, including anaphylaxis. | (5) Strategies for reducing the risk of exposure to | anaphylactic causative agents, including food and other | allergens. | (6) A communication plan for discussion with children | who have developed adequate verbal communication and | comprehension skills and with the parents or guardians of | all children about foods that are safe and unsafe and | about strategies to avoid exposure to unsafe food. |
| (c) At least once each calendar year, each school district | shall send a notification to the parents or guardians of all | children under the care of a school to make them aware of the | anaphylactic policy. The notification shall include contact | information for parents and guardians to engage further with | the school to learn more about individualized aspects of the | policy. | (d) At least 6 months after the effective date of this | amendatory Act of the 102nd General Assembly, the anaphylactic | policy established under subsection (a) shall be forwarded by | the State Board to the school board of each school district in | this State. Each school district shall implement or update, as | appropriate, its anaphylactic policy in accordance with those | developed by the State Board within 6 months after receiving | the anaphylactic policy from the State Board. | (e) The anaphylactic policy established under subsection | (a) shall be reviewed and updated, if necessary, at least once | every 3 years. | (f) The State Board shall post the anaphylactic policy | established under subsection (a) and resources regarding | allergies and anaphylaxis on its website. | (g) The State Board may adopt any rules necessary to | implement this Section.
| (105 ILCS 5/22-30)
| Sec. 22-30. Self-administration and self-carry of asthma |
| medication and epinephrine injectors; administration of | undesignated epinephrine injectors; administration of an | opioid antagonist; administration of undesignated asthma | medication; asthma episode emergency response protocol.
| (a) For the purpose of this Section only, the following | terms shall have the meanings set forth below:
| "Asthma action plan" means a written plan developed with a | pupil's medical provider to help control the pupil's asthma. | The goal of an asthma action plan is to reduce or prevent | flare-ups and emergency department visits through day-to-day | management and to serve as a student-specific document to be | referenced in the event of an asthma episode. | "Asthma episode emergency response protocol" means a | procedure to provide assistance to a pupil experiencing | symptoms of wheezing, coughing, shortness of breath, chest | tightness, or breathing difficulty. | "Epinephrine injector" includes an auto-injector approved | by the United States Food and Drug Administration for the | administration of epinephrine and a pre-filled syringe | approved by the United States Food and Drug Administration and | used for the administration of epinephrine that contains a | pre-measured dose of epinephrine that is equivalent to the | dosages used in an auto-injector. | "Asthma medication" means quick-relief asthma medication, | including albuterol or other short-acting bronchodilators, | that is approved by the United States Food and Drug |
| Administration for the treatment of respiratory distress. | "Asthma medication" includes medication delivered through a | device, including a metered dose inhaler with a reusable or | disposable spacer or a nebulizer with a mouthpiece or mask.
| "Opioid antagonist" means a drug that binds to opioid | receptors and blocks or inhibits the effect of opioids acting | on those receptors, including, but not limited to, naloxone | hydrochloride or any other similarly acting drug approved by | the U.S. Food and Drug Administration. | "Respiratory distress" means the perceived or actual | presence of wheezing, coughing, shortness of breath, chest | tightness, breathing difficulty, or any other symptoms | consistent with asthma. Respiratory distress may be | categorized as "mild-to-moderate" or "severe". | "School nurse" means a registered nurse working in a | school with or without licensure endorsed in school nursing. | "Self-administration" means a pupil's discretionary use of | his or
her prescribed asthma medication or epinephrine | injector.
| "Self-carry" means a pupil's ability to carry his or her | prescribed asthma medication or epinephrine injector. | "Standing protocol" may be issued by (i) a physician | licensed to practice medicine in all its branches, (ii) a | licensed physician assistant with prescriptive authority, or | (iii) a licensed advanced practice registered nurse with | prescriptive authority. |
| "Trained personnel" means any school employee or volunteer | personnel authorized in Sections 10-22.34, 10-22.34a, and | 10-22.34b of this Code who has completed training under | subsection (g) of this Section to recognize and respond to | anaphylaxis, an opioid overdose, or respiratory distress. | "Undesignated asthma medication" means asthma medication | prescribed in the name of a school district, public school, | charter school, or nonpublic school. | "Undesignated epinephrine injector" means an epinephrine | injector prescribed in the name of a school district, public | school, charter school, or nonpublic school. | (b) A school, whether public, charter, or nonpublic, must | permit the
self-administration and self-carry of asthma
| medication by a pupil with asthma or the self-administration | and self-carry of an epinephrine injector by a pupil, provided | that:
| (1) the parents or
guardians of the pupil provide to | the school (i) written
authorization from the parents or | guardians for (A) the self-administration and self-carry | of asthma medication or (B) the self-carry of asthma | medication or (ii) for (A) the self-administration and | self-carry of an epinephrine injector or (B) the | self-carry of an epinephrine injector, written | authorization from the pupil's physician, physician | assistant, or advanced practice registered nurse; and
| (2) the
parents or guardians of the pupil provide to |
| the school (i) the prescription label, which must contain | the name of the asthma medication, the prescribed dosage, | and the time at which or circumstances under which the | asthma medication is to be administered, or (ii) for the | self-administration or self-carry of an epinephrine | injector, a
written
statement from the pupil's physician, | physician assistant, or advanced practice registered
nurse | containing
the following information:
| (A) the name and purpose of the epinephrine | injector;
| (B) the prescribed dosage; and
| (C) the time or times at which or the special | circumstances
under which the epinephrine injector is | to be administered.
| The information provided shall be kept on file in the office of | the school
nurse or,
in the absence of a school nurse, the | school's administrator.
| (b-5) A school district, public school, charter school, or | nonpublic school may authorize the provision of a | student-specific or undesignated epinephrine injector to a | student or any personnel authorized under a student's | Individual Health Care Action Plan, Illinois Food Allergy | Emergency Action Plan and Treatment Authorization Form, or | plan pursuant to Section 504 of the federal Rehabilitation Act | of 1973 to administer an epinephrine injector to the student, | that meets the student's prescription on file. |
| (b-10) The school district, public school, charter school, | or nonpublic school may authorize a school nurse or trained | personnel to do the following: (i) provide an undesignated | epinephrine injector to a student for self-administration only | or any personnel authorized under a student's Individual | Health Care Action Plan, Illinois Food Allergy Emergency | Action Plan and Treatment Authorization Form, plan pursuant to | Section 504 of the federal Rehabilitation Act of 1973, or | individualized education program plan to administer to the | student that meets the student's prescription on file; (ii) | administer an undesignated epinephrine injector that meets the | prescription on file to any student who has an Individual | Health Care Action Plan, Illinois Food Allergy Emergency | Action Plan and Treatment Authorization Form, plan pursuant to | Section 504 of the federal Rehabilitation Act of 1973, or | individualized education program plan that authorizes the use | of an epinephrine injector; (iii) administer an undesignated | epinephrine injector to any person that the school nurse or | trained personnel in good faith believes is having an | anaphylactic reaction; (iv) administer an opioid antagonist to | any person that the school nurse or trained personnel in good | faith believes is having an opioid overdose; (v) provide | undesignated asthma medication to a student for | self-administration only or to any personnel authorized under | a student's Individual Health Care Action Plan or asthma | action plan, plan pursuant to Section 504 of the federal |
| Rehabilitation Act of 1973, or individualized education | program plan to administer to the student that meets the | student's prescription on file; (vi) administer undesignated | asthma medication that meets the prescription on file to any | student who has an Individual Health Care Action Plan or | asthma action plan, plan pursuant to Section 504 of the | federal Rehabilitation Act of 1973, or individualized | education program plan that authorizes the use of asthma | medication; and (vii) administer undesignated asthma | medication to any person that the school nurse or trained | personnel believes in good faith is having respiratory | distress. | (c) The school district, public school, charter school, or | nonpublic school must inform the parents or
guardians of the
| pupil, in writing, that the school district, public school, | charter school, or nonpublic school and its
employees and
| agents, including a physician, physician assistant, or | advanced practice registered nurse providing standing protocol | and a prescription for school epinephrine injectors, an opioid | antagonist, or undesignated asthma medication,
are to incur no | liability or professional discipline, except for willful and | wanton conduct, as a result
of any injury arising from the
| administration of asthma medication, an epinephrine injector, | or an opioid antagonist regardless of whether authorization | was given by the pupil's parents or guardians or by the pupil's | physician, physician assistant, or advanced practice |
| registered nurse. The parents or guardians
of the pupil must | sign a statement acknowledging that the school district, | public school, charter school,
or nonpublic school and its | employees and agents are to incur no liability, except for | willful and wanton
conduct, as a result of any injury arising
| from the
administration of asthma medication, an epinephrine | injector, or an opioid antagonist regardless of whether | authorization was given by the pupil's parents or guardians or | by the pupil's physician, physician assistant, or advanced | practice registered nurse and that the parents or
guardians | must indemnify and hold harmless the school district, public | school, charter school, or nonpublic
school and
its
employees | and agents against any claims, except a claim based on willful | and
wanton conduct, arising out of the
administration of | asthma medication, an epinephrine injector, or an opioid | antagonist regardless of whether authorization was given by | the pupil's parents or guardians or by the pupil's physician, | physician assistant, or advanced practice registered nurse. | (c-5) When a school nurse or trained personnel administers | an undesignated epinephrine injector to a person whom the | school nurse or trained personnel in good faith believes is | having an anaphylactic reaction, administers an opioid | antagonist to a person whom the school nurse or trained | personnel in good faith believes is having an opioid overdose, | or administers undesignated asthma medication to a person whom | the school nurse or trained personnel in good faith believes |
| is having respiratory distress, notwithstanding the lack of | notice to the parents or guardians of the pupil or the absence | of the parents or guardians signed statement acknowledging no | liability, except for willful and wanton conduct, the school | district, public school, charter school, or nonpublic school | and its employees and agents, and a physician, a physician | assistant, or an advanced practice registered nurse providing | standing protocol and a prescription for undesignated | epinephrine injectors, an opioid antagonist, or undesignated | asthma medication, are to incur no liability or professional | discipline, except for willful and wanton conduct, as a result | of any injury arising from the use of an undesignated | epinephrine injector, the use of an opioid antagonist, or the | use of undesignated asthma medication, regardless of whether | authorization was given by the pupil's parents or guardians or | by the pupil's physician, physician assistant, or advanced | practice registered nurse.
| (d) The permission for self-administration and self-carry | of asthma medication or the self-administration and self-carry | of an epinephrine injector is effective
for the school year | for which it is granted and shall be renewed each
subsequent | school year upon fulfillment of the requirements of this
| Section.
| (e) Provided that the requirements of this Section are | fulfilled, a
pupil with asthma may self-administer and | self-carry his or her asthma medication or a pupil may |
| self-administer and self-carry an epinephrine injector (i) | while in
school, (ii) while at a school-sponsored activity, | (iii) while under the
supervision of
school personnel, or (iv) | before or after normal school activities, such
as while in | before-school or after-school care on school-operated
property | or while being transported on a school bus.
| (e-5) Provided that the requirements of this Section are | fulfilled, a school nurse or trained personnel may administer | an undesignated epinephrine injector to any person whom the | school nurse or trained personnel in good faith believes to be | having an anaphylactic reaction (i) while in school, (ii) | while at a school-sponsored activity, (iii) while under the | supervision of school personnel, or (iv) before or after | normal school activities, such
as while in before-school or | after-school care on school-operated property or while being | transported on a school bus. A school nurse or trained | personnel may carry undesignated epinephrine injectors on his | or her person while in school or at a school-sponsored | activity. | (e-10) Provided that the requirements of this Section are | fulfilled, a school nurse or trained personnel may administer | an opioid antagonist to any person whom the school nurse or | trained personnel in good faith believes to be having an | opioid overdose (i) while in school, (ii) while at a | school-sponsored activity, (iii) while under the supervision | of school personnel, or (iv) before or after normal school |
| activities, such as while in before-school or after-school | care on school-operated property. A school nurse or trained | personnel may carry an opioid antagonist on his or her person | while in school or at a school-sponsored activity. | (e-15) If the requirements of this Section are met, a | school nurse or trained personnel may administer undesignated | asthma medication to any person whom the school nurse or | trained personnel in good faith believes to be experiencing | respiratory distress (i) while in school, (ii) while at a | school-sponsored activity, (iii) while under the supervision | of school personnel, or (iv) before or after normal school | activities, including before-school or after-school care on | school-operated property. A school nurse or trained personnel | may carry undesignated asthma medication on his or her person | while in school or at a school-sponsored activity. | (f) The school district, public school, charter school, or | nonpublic school may maintain a supply of undesignated | epinephrine injectors in any secure location that is | accessible before, during, and after school where an allergic | person is most at risk, including, but not limited to, | classrooms and lunchrooms. A physician, a physician assistant | who has prescriptive authority in accordance with Section 7.5 | of the Physician Assistant Practice Act of 1987, or an | advanced practice registered nurse who has prescriptive | authority in accordance with Section 65-40 of the Nurse | Practice Act may prescribe undesignated epinephrine injectors |
| in the name of the school district, public school, charter | school, or nonpublic school to be maintained for use when | necessary. Any supply of epinephrine injectors shall be | maintained in accordance with the manufacturer's instructions. | The school district, public school, charter school, or | nonpublic school may maintain a supply of an opioid antagonist | in any secure location where an individual may have an opioid | overdose. A health care professional who has been delegated | prescriptive authority for opioid antagonists in accordance | with Section 5-23 of the Substance Use Disorder Act may | prescribe opioid antagonists in the name of the school | district, public school, charter school, or nonpublic school, | to be maintained for use when necessary. Any supply of opioid | antagonists shall be maintained in accordance with the | manufacturer's instructions. | The school district, public school, charter school, or | nonpublic school may maintain a supply of asthma medication in | any secure location that is accessible before, during, or | after school where a person is most at risk, including, but not | limited to, a classroom or the nurse's office. A physician, a | physician assistant who has prescriptive authority under | Section 7.5 of the Physician Assistant Practice Act of 1987, | or an advanced practice registered nurse who has prescriptive | authority under Section 65-40 of the Nurse Practice Act may | prescribe undesignated asthma medication in the name of the | school district, public school, charter school, or nonpublic |
| school to be maintained for use when necessary. Any supply of | undesignated asthma medication must be maintained in | accordance with the manufacturer's instructions. | (f-3) Whichever entity initiates the process of obtaining | undesignated epinephrine injectors and providing training to | personnel for carrying and administering undesignated | epinephrine injectors shall pay for the costs of the | undesignated epinephrine injectors. | (f-5) Upon any administration of an epinephrine injector, | a school district, public school, charter school, or nonpublic | school must immediately activate the EMS system and notify the | student's parent, guardian, or emergency contact, if known. | Upon any administration of an opioid antagonist, a school | district, public school, charter school, or nonpublic school | must immediately activate the EMS system and notify the | student's parent, guardian, or emergency contact, if known. | (f-10) Within 24 hours of the administration of an | undesignated epinephrine injector, a school district, public | school, charter school, or nonpublic school must notify the | physician, physician assistant, or advanced practice | registered nurse who provided the standing protocol and a | prescription for the undesignated epinephrine injector of its | use. | Within 24 hours after the administration of an opioid | antagonist, a school district, public school, charter school, | or nonpublic school must notify the health care professional |
| who provided the prescription for the opioid antagonist of its | use. | Within 24 hours after the administration of undesignated | asthma medication, a school district, public school, charter | school, or nonpublic school must notify the student's parent | or guardian or emergency contact, if known, and the physician, | physician assistant, or advanced practice registered nurse who | provided the standing protocol and a prescription for the | undesignated asthma medication of its use. The district or | school must follow up with the school nurse, if available, and | may, with the consent of the child's parent or guardian, | notify the child's health care provider of record, as | determined under this Section, of its use. | (g) Prior to the administration of an undesignated | epinephrine injector, trained personnel must submit to the | school's administration proof of completion of a training | curriculum to recognize and respond to anaphylaxis that meets | the requirements of subsection (h) of this Section. Training | must be completed annually. The school district, public | school, charter school, or nonpublic school must maintain | records related to the training curriculum and trained | personnel. | Prior to the administration of an opioid antagonist, | trained personnel must submit to the school's administration | proof of completion of a training curriculum to recognize and | respond to an opioid overdose, which curriculum must meet the |
| requirements of subsection (h-5) of this Section. Training | must be completed annually. Trained personnel must also submit | to the school's administration proof of cardiopulmonary | resuscitation and automated external defibrillator | certification. The school district, public school, charter | school, or nonpublic school must maintain records relating to | the training curriculum and the trained personnel. | Prior to the administration of undesignated asthma | medication, trained personnel must submit to the school's | administration proof of completion of a training curriculum to | recognize and respond to respiratory distress, which must meet | the requirements of subsection (h-10) of this Section. | Training must be completed annually, and the school district, | public school, charter school, or nonpublic school must | maintain records relating to the training curriculum and the | trained personnel. | (h) A training curriculum to recognize and respond to | anaphylaxis, including the administration of an undesignated | epinephrine injector, may be conducted online or in person. | Training shall include, but is not limited to: | (1) how to recognize signs and symptoms of an allergic | reaction, including anaphylaxis; | (2) how to administer an epinephrine injector; and | (3) a test demonstrating competency of the knowledge | required to recognize anaphylaxis and administer an | epinephrine injector. |
| Training may also include, but is not limited to: | (A) a review of high-risk areas within a school and | its related facilities; | (B) steps to take to prevent exposure to allergens; | (C) emergency follow-up procedures, including the | importance of calling 9-1-1 or, if 9-1-1 is not available, | other local emergency medical services; | (D) how to respond to a student with a known allergy, | as well as a student with a previously unknown allergy; | and | (E) other criteria as determined in rules adopted | pursuant to this Section ; and . | (F) any policy developed by the State Board of | Education under Section 2-3.182. | In consultation with statewide professional organizations | representing physicians licensed to practice medicine in all | of its branches, registered nurses, and school nurses, the | State Board of Education shall make available resource | materials consistent with criteria in this subsection (h) for | educating trained personnel to recognize and respond to | anaphylaxis. The State Board may take into consideration the | curriculum on this subject developed by other states, as well | as any other curricular materials suggested by medical experts | and other groups that work on life-threatening allergy issues. | The State Board is not required to create new resource | materials. The State Board shall make these resource materials |
| available on its Internet website. | (h-5) A training curriculum to recognize and respond to an | opioid overdose, including the administration of an opioid | antagonist, may be conducted online or in person. The training | must comply with any training requirements under Section 5-23 | of the Substance Use Disorder Act and the corresponding rules. | It must include, but is not limited to: | (1) how to recognize symptoms of an opioid overdose; | (2) information on drug overdose prevention and | recognition; | (3) how to perform rescue breathing and resuscitation; | (4) how to respond to an emergency involving an opioid | overdose; | (5) opioid antagonist dosage and administration; | (6) the importance of calling 9-1-1 or, if 9-1-1 is | not available, other local emergency medical services; | (7) care for the overdose victim after administration | of the overdose antagonist; | (8) a test demonstrating competency of the knowledge | required to recognize an opioid overdose and administer a | dose of an opioid antagonist; and | (9) other criteria as determined in rules adopted | pursuant to this Section. | (h-10) A training curriculum to recognize and respond to | respiratory distress, including the administration of | undesignated asthma medication, may be conducted online or in |
| person. The training must include, but is not limited to: | (1) how to recognize symptoms of respiratory distress | and how to distinguish respiratory distress from | anaphylaxis; | (2) how to respond to an emergency involving | respiratory distress; | (3) asthma medication dosage and administration; | (4) the importance of calling 9-1-1 or, if 9-1-1 is | not available, other local emergency medical services; | (5) a test demonstrating competency of the knowledge | required to recognize respiratory distress and administer | asthma medication; and | (6) other criteria as determined in rules adopted | under this Section. | (i) Within 3 days after the administration of an | undesignated epinephrine injector by a school nurse, trained | personnel, or a student at a school or school-sponsored | activity, the school must report to the State Board of | Education in a form and manner prescribed by the State Board | the following information: | (1) age and type of person receiving epinephrine | (student, staff, visitor); | (2) any previously known diagnosis of a severe | allergy; | (3) trigger that precipitated allergic episode; | (4) location where symptoms developed; |
| (5) number of doses administered; | (6) type of person administering epinephrine (school | nurse, trained personnel, student); and | (7) any other information required by the State Board. | If a school district, public school, charter school, or | nonpublic school maintains or has an independent contractor | providing transportation to students who maintains a supply of | undesignated epinephrine injectors, then the school district, | public school, charter school, or nonpublic school must report | that information to the State Board of Education upon adoption | or change of the policy of the school district, public school, | charter school, nonpublic school, or independent contractor, | in a manner as prescribed by the State Board. The report must | include the number of undesignated epinephrine injectors in | supply. | (i-5) Within 3 days after the administration of an opioid | antagonist by a school nurse or trained personnel, the school | must report to the State Board of Education, in a form and | manner prescribed by the State Board, the following | information: | (1) the age and type of person receiving the opioid | antagonist (student, staff, or visitor); | (2) the location where symptoms developed; | (3) the type of person administering the opioid | antagonist (school nurse or trained personnel); and | (4) any other information required by the State Board. |
| (i-10) Within 3 days after the administration of | undesignated asthma medication by a school nurse, trained | personnel, or a student at a school or school-sponsored | activity, the school must report to the State Board of | Education, on a form and in a manner prescribed by the State | Board of Education, the following information: | (1) the age and type of person receiving the asthma | medication (student, staff, or visitor); | (2) any previously known diagnosis of asthma for the | person; | (3) the trigger that precipitated respiratory | distress, if identifiable; | (4) the location of where the symptoms developed; | (5) the number of doses administered; | (6) the type of person administering the asthma | medication (school nurse, trained personnel, or student); | (7) the outcome of the asthma medication | administration; and | (8)
any other information required by the State Board. | (j) By October 1, 2015 and every year thereafter, the | State Board of Education shall submit a report to the General | Assembly identifying the frequency and circumstances of | undesignated epinephrine and undesignated asthma medication | administration during the preceding academic year. Beginning | with the 2017 report, the report shall also contain | information on which school districts, public schools, charter |
| schools, and nonpublic schools maintain or have independent | contractors providing transportation to students who maintain | a supply of undesignated epinephrine injectors. This report | shall be published on the State Board's Internet website on | the date the report is delivered to the General Assembly. | (j-5) Annually, each school district, public school, | charter school, or nonpublic school shall request an asthma | action plan from the parents or guardians of a pupil with | asthma. If provided, the asthma action plan must be kept on | file in the office of the school nurse or, in the absence of a | school nurse, the school administrator. Copies of the asthma | action plan may be distributed to appropriate school staff who | interact with the pupil on a regular basis, and, if | applicable, may be attached to the pupil's federal Section 504 | plan or individualized education program plan. | (j-10) To assist schools with emergency response | procedures for asthma, the State Board of Education, in | consultation with statewide professional organizations with | expertise in asthma management and a statewide organization | representing school administrators, shall develop a model | asthma episode emergency response protocol before September 1, | 2016. Each school district, charter school, and nonpublic | school shall adopt an asthma episode emergency response | protocol before January 1, 2017 that includes all of the | components of the State Board's model protocol. | (j-15) Every 2 years, school personnel who work with |
| pupils shall complete an in-person or online training program | on the management of asthma, the prevention of asthma | symptoms, and emergency response in the school setting. In | consultation with statewide professional organizations with | expertise in asthma management, the State Board of Education | shall make available resource materials for educating school | personnel about asthma and emergency response in the school | setting. | (j-20) On or before October 1, 2016 and every year | thereafter, the State Board of Education shall submit a report | to the General Assembly and the Department of Public Health | identifying the frequency and circumstances of opioid | antagonist administration during the preceding academic year. | This report shall be published on the State Board's Internet | website on the date the report is delivered to the General | Assembly. | (k) The State Board of Education may adopt rules necessary | to implement this Section. | (l) Nothing in this Section shall limit the amount of | epinephrine injectors that any type of school or student may | carry or maintain a supply of. | (Source: P.A. 100-201, eff. 8-18-17; 100-513, eff. 1-1-18; | 100-726, eff. 1-1-19; 100-759, eff. 1-1-19; 100-799, eff. | 1-1-19; 101-81, eff. 7-12-19.)
| (105 ILCS 5/2-3.149 rep.) |
| Section 905. The School Code is amended by repealing | Section 2-3.149. | Section 910. The Child Care Act of 1969 is amended by | adding Section 5.11 as follows: | (225 ILCS 10/5.11 new) | Sec. 5.11. Plan for anaphylactic shock. The Department | shall require each licensed day care center, day care home, | and group day care home to have a plan for anaphylactic shock | to be followed for the prevention of anaphylaxis and during a | medical emergency resulting from anaphylaxis. The plan should | be based on the guidance and recommendations provided by the | American Academy of Pediatrics relating to the management of | food allergies or other allergies. The plan should be shared | with parents or guardians upon enrollment at each licensed day | care center, day care home, and group day care home. If a child | requires specific specialized treatment during an episode of | anaphylaxis, that child's treatment plan should be kept by the | staff of the day care center, day care home, or group day care | home and followed in the event of an emergency. Each licensed | day care center, day care home, and group day care home shall | have at least one staff member present at all times who has | taken a training course in recognizing and responding to | anaphylaxis.
| Section 999. Effective date. This Act takes effect July 1, |
Effective Date: 8/20/2021
|